BOSTON SCIENTIFIC CORP — Director's Dealing 2020

Sep 14, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BOSTON SCIENTIFIC CORP (BSX)
CIK: 0000885725
Period of Report: 2020-09-11

Reporting Person: Fitzgerald Joseph Michael (EVP & Pres, Interven Cardio)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-09-11	Common Stock	M	77640.0000	$7.1600	Acquired	298688.0000	Direct
2020-09-11	Common Stock	S	77640.0000	$40.7606	Disposed	221048.0000	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-09-11	Stock Option (Right to Buy)	$7.1600	M	77640.0000	Disposed	2021-02-28	Common Stock (77640.0000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	68297.0000	Indirect
Common Stock	6777.0000	Indirect

Footnotes

F1: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan.

F2: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $40.54 to $41.05, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

F3: Balance reflects the most current data available with regard to share holdings in the Company's 401(k) Retirement Savings Plan.

F4: The reporting person disclaims beneficial ownership of the shares held by his children, and this report should not be deemed an admission that the reporting person is the beneficial owner of his children's shares for purposes of Section 16 or for any other purpose.

F5: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 28, 2012, the first anniversary of the grant.